With the natural growth of population, aging demographics, and increasing awareness of health and hygiene among residents in China, as well as the continuous updates and improvements in medical facility technologies and growing public concern for healthcare, China's biopharmaceutical and healthcare industries are experiencing sustained and rapid development. In December 2016, the State Council issued the "13th Five-Year Plan" for Deepening the Reform of the Medical and Healthcare System, requiring that during the "13th Five-Year Plan" period, new breakthroughs be made in the construction of five systems: tiered healthcare, modern hospital management, universal healthcare, drug supply security, and comprehensive supervision, while reforms be coordinated in related fields. These measures will further expand the market size of drug demand and accelerate the rapid development of basic healthcare industries such as modern hospitals, elderly care, and rehabilitation centers.